Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Survodutide

BI 456906 · Survodutide

Animal replicated

Research chemicalGLP-1/Glucagon Dual Agonist Peptide Anti-Obesity Drug

RouteInjectableGray-market only

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: BI 456906 — Dual GLP-1 / Glucagon Receptor Agonist — Boehringer Ingelheim / Zealand Pharma — GLP-1/Glucagon Dual Agonist, Peptide, Anti-Obesity Drug.
Why people use it: Used primarily for weight loss and gut health.

If you only read one thing

Survodutide is Boehringer Ingelheim's bet that the glucagon receptor — not the GIP receptor — is the right second partner for GLP-1 in treating metabolic liver disease. Tirzepatide went GLP-1 + GIP and produced the highest approved weight loss efficacy. Survodutide went GLP-1 + glucagon and produced striking MASH resolution in Phase 2 (62% vs 14% placebo). The two dual-agonist strategies are not competing head-to-head — they are targeting different dimensions of the same metabolic disease cluster. GLP-1 + GIP: superior pure weight loss. GLP-1 + glucagon: potentially superior liver disease resolution through direct hepatic fat oxidation. For the enormous population of people with both obesity and MASH — estimated at hundreds of millions worldwide — the question of which dual mechanism produces better liver outcomes is one of the most important unanswered questions in metabolic pharmacology. Phase 3 LIVERAGE (MASH) will answer it.

Check interactions →

Published literature

3human RCTs0human studies1animal0in vitro

Counts include controlled Phase 2 obesity/T2D and MASH/NASH clinical programs; Phase 3 obesity/MASH programs are not counted until completed/published.

Evidence reality check

Human evidence

3 human studies

3 randomized; 0 observational.

Preclinical base

1 lab signal

1 animal; 0 in-vitro/mechanistic.

Risk posture

No major flags listed

Review route-specific cautions before use.

Categories

Weight Loss & Metabolic Gut & Digestive Mitochondrial & Energy

Properties

✓ Human RCT

Evidence

CAnimal replicated

The Latest Data (May 2026)

Phase 3 SYNCHRONIZE-1 (April 29, 2026): obesity without T2D; 76 weeks; survodutide achieved -16.6% mean weight loss vs -3.2% placebo (p<0.0001); co-primary endpoints met using both efficacy and treatment-regimen estimands; mean weight loss 17.8 kg (39.2 lb). Full data presentation at ADA Scientific Sessions June 2026. Phase 2 MASH (NEJM July 2024; Sanyal et al.; doi:10.1056/NEJMoa2401755): n=293; 48 weeks; MASH resolution without fibrosis worsening: 62% at 4.8mg vs 14% placebo (p<0.001); ≥30% liver fat reduction: 67% vs 14%; fibrosis improvement ≥1 stage: 36% vs 22%.

FDA and Regulatory Status

FDA Fast Track Designation: 2021 (MASH). FDA Breakthrough Therapy Designation: September 2024 (MASH, non-cirrhotic, fibrosis stages 2-3). China NMPA Breakthrough Therapy: June 2024. Taiwan FDA Breakthrough Designation: September 2024. Phase 3 LIVERAGE (MASH): started October 2024. Phase 3 SYNCHRONIZE program (obesity): ongoing, SYNCHRONIZE-1 topline positive April 2026. Phase 3 LIVERAGE-Cirrhosis: fibrosis stage 4. SYNCHRONIZE-CVOT: long-term cardiovascular safety. Estimated FDA approval: 2027 at earliest.

The Glucagon Component — Why It Matters

Glucagon is historically considered the 'counter-regulatory' hormone to insulin — it raises blood glucose, triggers glycogenolysis, and drives gluconeogenesis. This made glucagon receptor agonism seem counterproductive in metabolic disease. The survodutide story is glucagon's rehabilitation: when GLP-1 and glucagon receptor agonism are combined at the right ratio, GLP-1 manages the hyperglycemic risk from glucagon while glucagon's direct hepatic fat-oxidizing and thermogenic effects produce superior metabolic outcomes. The hepatocyte glucagon receptor drives: lipolysis of liver fat; increased fatty acid beta-oxidation in hepatic mitochondria; reduced hepatic lipogenesis; these are precisely the mechanisms needed to treat MASH, where excess liver fat is the pathological substrate.

Community Status

Survodutide is not currently widely available as a research chemical — it is a novel pharmaceutical in active Phase 3 development. Unlike some compounds in this reference where the research chemical community precedes the clinical program, survodutide's community use is minimal. It is included in this reference because: (1) it represents the most significant obesity/MASH pipeline compound not yet approved; (2) it illustrates the GLP-1/glucagon dual mechanism in detail; (3) for community members with MASH, understanding this pipeline is essential for informed decision-making about current vs future treatment options.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

Mazdutide

Same class · GLP-1/Glucagon Dual Agonist

The World's First Approved Dual GCG/GLP-1 Receptor Agonist. NMPA-Approved in China June 2025 for Obesity. Second NMPA Approval September 2025 for T2D. Phase 3 T2D Data Published Back-to-Back in Nature December 2025. Originally Eli Lilly's LY3305677 — Licensed to Innovent Biologics for China Development. No FDA Submission as of Mid-2026. The Drug That Is Simultaneously Approved, Unavailable, and a Research Chemical Depending on Where You Are.

Retatrutide

Same class · Peptide

28.7% Weight Loss in Phase 3. The Most Effective Weight Loss Drug Ever Trialed. Not Approved. Not Available by Prescription. The Community Is Already Using It. And It Is Not the Same Drug as Tirzepatide.

Cagrilintide